Navigation Links
Phase II trails of new HIV vaccine to be held in South Africa

In a step further to combat the AIDS epidemic, South Africa's first Phase II HIV vaccine trials were launched by charitable group the International AIDS Vaccine Initiative (IAVI) and U.S.-based Targeted Genetics Corporation. //

The trials will test the safety of "tgAAC09" is a preventive HIV vaccine candidate that is based on HIV subtype C, the subtype of the virus most prevalent in southern and eastern Africa, the two groups said in a joint statement on Monday.

Sub-Saharan Africa is the region hardest hit by AIDS, with more than 25 million people estimated to be infected with HIV, the virus that leads to the disease.

South Africa has the highest caseload of HIV in the world, with about one in nine of its 45 million population carrying the virus, while in neighbouring Botswana and Swaziland prevalence is as high as 40 percent.

"We are pleased that South Africa has taken a leading role in the testing of vaccine candidates given the medical and humanitarian promise a preventative vaccine holds," said Eftyhia Vardas, a doctor at the country's Perinatal HIV Research Unit, who will coordinate the trials.

Investigators test the immune response and acquire more data on safety during second phase trials on drugs that have already been proven safe during first phase tests. tgAAC09 is designed to elicit two different types of immune responses, an antibody response and a cell mediated response. The vaccine consists of an artificially made copy of the HIV virus and cannot cause HIV infection or Aids," the IAVI said on Monday.

The vaccine candidate, developed by U.S.-based Targeted Genetics, will be tested on 78 healthy volunteers at three sites in South Africa. The trial is expected to last 18 months.

IAVI, a global non-profit organisation working to accelerate the development of an AIDS vaccine, estimates that around 30 preventative HIV vaccine candidates are in human trials in six continents.


'"/>




Page: 1 2

Related medicine news :

1. SARS-Free Taiwan to Mark End Phase of Global Fight
2. Spray on contraceptive clears Phase I trial
3. Phase 3 trials of two multi-kinase inhibitors against cancer
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. FDA approves Phase 0 trial which tests experimental drugs on humans
6. Jalgaon: Third Phase Of Culling Operations Begin
7. Phase 1 Drug Trials on Humans to Be Made Public
8. Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P
9. Cadila to Commence Phase I Clinical Trials On ZYH2
10. iGATE Completes Phase I Testing Of Meningitis Vaccine
11. ADHD Treatment -Phase 3 data on Lisdexamfetamine dimesylate Presented
Post Your Comments:
(Date:10/7/2008)...t in post-HAART era , , TUESDAY, Oct. 7 ...earch finds little evidence that circumcision prot...ut the issue is still far from settled. , For o...werful AIDS drugs showed that circumcision did hav...nched the most definitive type of research into th...
(Date:10/7/2008)...ter at the University of California, San Diego (UC...less march of advanced lung cancer by treating pat...any vaccines attempt to pump up the immune system ...s genetically engineered to also trick the cancer ...ivities. , The first patients have begun enrolli...
(Date:10/7/2008)...quest comes at stem cell symposium, ANN ARBOR, Mi...ne year,ago, retail pioneer A. Alfred Taubman anno...igan, to endow a new research institute aimed at,u...e., Today, at the institute,s first symposium, he...an additional $22 million to the,University for th...
(Date:10/7/2008)...E NATION HAVE SAID ,I VOTE FOR THE ...ire/ -- To aid and help educate tonight,s debate,w...idential candidates,Senators John McCain and Barac...Susan G. Komen for the Cure(R) Advocacy Alliance t...ts web site --, http://www.IVotefortheCure.org ., ...
Breaking Medicine News(10 mins):Health News:Role of Circumcision in Reducing HIV Risk Still Unclear 2Health News:Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center 2Health News:Alfred Taubman Announces New $22M Gift to U-M 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Educates Voters, Debate Watchers on McCain/Obama Health Care Agendas 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Educates Voters, Debate Watchers on McCain/Obama Health Care Agendas 3
...vidence to implicate insulin-like growth factor re...ase.// In a previous research, Terry J. Smith, M.... the interaction between immunoglobulins and IGF-1...ocyte infiltration in both Graves’ disease and rhe...
...ind a cure for deafness. As a leader in stem cell-...iversity School of Medicine,// he's got a step-by-... take another decade or so, but if anyone can do i...ur bets on. 'Everyone asks, 'How long before we d...
...tion of East Caribbean States (OECS) have said sch...ntion studies to their respective curricula. Arse... pandemic has raised concern of great magnitude in...tistics, the year 2006 saw 170,000 new cases of in...
...ally Administered Tribal Area (FARA) was the secon...t the immunization //drive carried out by the gove... chief surgeon at the main government hospital in ...olled roadside bomb exploded in Salarzai, a villag...
Other Medicine News:Health News:A Single Biological Mechanism Behind Several Autoimmune Disorders 2Health News:Stem Cell Transplants Explored as a Possible Treatment for Hearing Loss 2
(Date:10/7/2008)...tCall/ -- CEL-SCI Corporation,(NYSE: CVM ) announ...sfer,Agreement (MTA) with the National Institutes ...ry of Dr. Francesco M. Marincola, M.D., to,investi...icroenvironment,caused by CEL-SCI,s cancer drug Mu...ous Disease and Immunogentics Section, Department ...
(Date:10/7/2008).../ -- Aerovance Inc. today reported,pharmacokinetic...Aerovant,inhalation powder that demonstrate good t...llowing asthma patients, inhalation of a single 10... three doses investigated in,Aerovance,s Phase IIb...arly,next year. Evidence gathered from nonclinical...
(Date:10/7/2008)... Tests for Use on the GeneXpert(R) ...7 /- Cepheid (Nasdaq:,CPHD)...B as a European CE,IVD Mark product under the Euro...ces. The test delivers rapid detection of vanA and... with vancomycin-resistant,enterococci (VRE) -- on...
(Date:10/6/2008)...e/ -- "A return to the use of,chimpanzees in AIDS ...ific,justification," according to a paper released...nimals (ATLA). "An Assessment of the Role of,Chimp...ccine responses in,chimpanzees are not predictive ...zees, critical role and importance in AIDS vaccine...
Breaking Medicine Technology:CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 2Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 3Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 4Research Attributes Lack of HIV/AIDS Vaccine to Use of Chimpanzees 2Salugen to Present at Nutrition Capital Networks First In Person Investor Meeting 1154 1Salugen to Present at Nutrition Capital Networks First In Person Investor Meeting 1154 2University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement 1152 1University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement 1152 2University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement 1152 3Prostate cancer more likely to return in blacks than whites but the disease is not more aggressive 3212 1Prostate cancer more likely to return in blacks than whites but the disease is not more aggressive 3212 2Fruit and vegetables health 3210 1
...fety of Gene Therapy in Lipoprotein Lipase,Deficie... 31, 2007 - Amsterdam Molecular,Therapeutics (AMT)...orted positive Phase I/II clinical trial results w...MT-011) in Complete,Lipoprotein Lipase (LPL) defic...erican Society of Gene Therapy (ASGT) in Seattle.,...
...rom XL880, Phase II data from XL999 studies,schedu...-, SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-F...ata from clinical trials of,the company,s investig...d at the 2007 American Society of Clinical Oncolog...1 to 5 in Chicago,Illinois. , , -- Data from t...
Other Medicine Technology:AMT Presents Positive Results of Phase I/II Study with Lead Product,at Annual Meeting of American Society of Gene Therapy 2AMT Presents Positive Results of Phase I/II Study with Lead Product,at Annual Meeting of American Society of Gene Therapy 3AMT Presents Positive Results of Phase I/II Study with Lead Product,at Annual Meeting of American Society of Gene Therapy 4Six Abstracts Featuring Exelixis Compounds Accepted At ASCO,Conference 2
...ontinuous low-flow nebulizer performance. Patented...allows for optimal medication and Heliox delivery ...vere asthma, COPD and pneumonia in both routine an... mouth and T-piece to deliver high-output, low-flo...
... diverse medical products for more than 58 years. ...anding reputation for innovation, quality and cust...ecognized brands include the Labtron® line of ... products, Bristoline® microscopes, HealthTeam...
...contains everything the health care professional n...ickly and efficiently: 7 nebulizers, T-piece and m...yringe and needle., ,Shipped 5 kits per case., ,...ed Use: AsthmaKit is a procedural kit providing th...
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only
Medicine Products: